TECOmedical Group

always your partner

Technical Information

M30 CytoDeath™ ELISA (PEVIVA®)

Measurement of soluble caspase-cleaved fragments of the intermediate filament protein keratin 18 (K18) containing the M30 neo-epitope (K18-Asp396-NE).

Released from human, monkey or bovine epithelial cells in cell culture.

Cat. No.:	10900
Tests:	96
Method:	ELISA
Range:	250 – 3000 U/L (units are defined against a synthetic peptide standard containing the M30 and M6 epitopes; 1 U/L = 1.24 pM)
LLOD:	60 U/L
Incubation time:	4.5 hours
Sample volume:	25 µl
Sample type:	cell cultures (epithelial cells)
Sample preparation:	Store samples at 2 – 8 °C up to 4 hours. For longer periods, store samples frozen at -20 °C or lower.
Species:	Human, primates

Intended Use:

Quantitative measurement of the apoptotic cell death biomarker K18-Asp396-NE in cell culture experiments. Can be used for cell lysates and/or culture supernatants. The assay only detects apoptosis in cells of epithelial origin that express K18. Cells should be of human, monkey or bovine origin.

To be used to determine accumulation of caspase-cleaved K18 (ccK18) in cell cultures, providing an integrative measure of apoptosis. The K18-Asp396 neo-epitope is formed by caspase-3, -7 or -9 activation.

*Note:

caspase-cleaved K18 = ccK18 previously Cytokeratin 18 (CK18/ccCK18)

References:

- Fayad W, *et al.* (2009). Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. *PLoS One* 4(10):e7238.
- Hernlund E, *et al.* (2009). Ovarian carcinoma cells with low levels of b-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. *Mol Cancer Ther* 2009;8(7).
- Herrmann R, *et al.* (2008). Screening for Compounds that Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids. *J Biomol Screen*. 13(1):1-8.
- Lakshmikanthan V, *et al.* (2006). SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. *Int J Cancer* 119:221-8.
- Cummings J, *et al.* (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. *Br J Cancer* 92, 532-538.
- Erdal H, *et al.* (2005). Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. *Proc. Natl. Acad. Sci. USA* 102, 192-197.
- Schutte B, *et al.* (2004). Keratin 8/18 breakdown and reorganization during apoptosis. *Exp Cell Res.* 297, 11-26.
- Kramer G, *et al.* (2004). Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18. *Cancer Research* 64, 1751-1756.
- Hägg, M. et al. (2002). A novel high-through-put assay for screening of pro-apoptotic drugs. *Invest. New Drugs*, 20: 253-259.
- Leers MP, *et al.* (1999). Immunocytochemical detection and mapping of a Cytokeratin 18 neo-epitope exposed during early apoptosis. *J Pathol* 187, 567-572.

For further information please contact / Für weitere Informationen wenden Sie sich bitte an /
Pour plus d´informations, veuillez contacter:

www.tecomedical.com

Certified Quality-System mdc ISO 13485

A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters
TECOmedical AG
Gewerbestrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany
TECOmedical GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux
TECOmedical Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria
TECOmedical AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com